Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2022-01-03 00:00:00 ET · period of report 2021-12-30 · accession 0001562180-22-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-03 | 2021-12-30 | SNDX | Meyers Michael L. | SVP, Chief Medical Off | M - OptEx | $8.77 | +5,900 | 21.6K | +38% | +$51.7K |
| D | 2022-01-03 | 2021-12-30 | SNDX | Meyers Michael L. | SVP, Chief Medical Off | M - OptEx | $0.00 | -5,900 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-30 | M | A | 5,900 | $8.77 | 21,566 | D | — | — | |
| 2 | Derivative | Stock Options (Right to buy) | 2021-12-30 | M | D | 5,900 | $0.00 | 0 | D | $8.77 · — to 2027-02-06 | 5,900 Common Stock | (F2) This option is fully vested. |